Health Catalyst (HCAT)
(Delayed Data from NSDQ)
$6.65 USD
-0.13 (-1.92%)
Updated May 8, 2024 04:00 PM ET
After-Market: $6.64 -0.01 (-0.15%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.65 USD
-0.13 (-1.92%)
Updated May 8, 2024 04:00 PM ET
After-Market: $6.64 -0.01 (-0.15%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
Health Catalyst (HCAT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 35% and 2.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Definitive Healthcare Corp. (DH) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Definitive Healthcare Corp. (DH) delivered earnings and revenue surprises of 20% and 1.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 72.73% and 1.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 25% and 3.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
RadNet (RDNT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
RadNet (RDNT) delivered earnings and revenue surprises of -650% and 1.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
IRhythm Technologies (IRTC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
iRhythm Technologies (IRTC) delivered earnings and revenue surprises of 24.53% and 5.97%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Inspire Medical Systems (INSP) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 21.79% and 6.95%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 9.52% and 2.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Axonics Modulation Technologies (AXNX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 5.56% and 6.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cerner (CERN) Q4 Earnings Top Estimates
by Zacks Equity Research
Cerner (CERN) delivered earnings and revenue surprises of 5.68% and 2.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics (TXG) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of -166.67% and 2.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 18.18% and 1.29%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Health Catalyst (HCAT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Health Catalyst (HCAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Health Catalyst, DocuSign, American Homes 4 Rent, MidAmerica Apartment Communities and Apartment Income REIT highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Health Catalyst, DocuSign, American Homes 4 Rent, MidAmerica Apartment Communities and Apartment Income REIT highlighted as Zacks Bull and Bear of the Day
Bull Of The Day: Heath Catalyst (HCAT)
by Brian Bolan
This stock had been reporting losses but posted a break-even quarter in the more recent print and that could start a new trend.
Cerner's (CERN) Latest Offering to Improve RCM Portfolio
by Zacks Equity Research
Cerner's (CERN) latest offering is likely to streamline and automate revenue cycle via interoperability and enhanced usability.
Health Catalyst (HCAT) Reports Break-Even Earnings for Q2
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 100.00% and 5.20%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Health Catalyst (HCAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for July 21st
by Zacks Equity Research
CNO, CLOV, DMAC, HCAT and IMAX have been added to the Zacks Rank #5 (Strong Sell) List on July 21, 2021.
Health Catalyst (HCAT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 53.85% and 3.25%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Health Catalyst (HCAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Health Catalyst (HCAT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Health Catalyst (HCAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Health Catalyst (HCAT) Catches Eye: Stock Jumps 5.1%
by Zacks Equity Research
Health Catalyst (HCAT) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Health Catalyst (HCAT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 22.22% and 5.69%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Health Catalyst (HCAT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Health Catalyst (HCAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.